Barclays lowered the firm’s price target on Iqvia to $245 from $250 and keeps an Overweight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IQV:
